Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN^?, ¡°eribulin¡±) will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.

 

Eisai will present five eribulin-related abstracts, including a post hoc subgroup analysis from two pivotal Phase 3 studies (EMBRACE and Study 301), as well as:

–??? Real world use of eribulin following treatment with a P13K inhibitor, mostly in people with Hormone Receptor (HR)-positive/HER2-negative metastatic breast cancer.

–??? Preclinical data exploring a liposomal formulation of eribulin, in a Phase 1 expansion cohort for breast cancer, versus eribulin at the same dose, in patient-derived breast cancer xenografts.

 

“We continue to relentlessly pursue research that provides useful insights for people living with breast cancer,¡± said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. ¡°A big part of this commitment is the ongoing sharing of our preclinical and clinical data with eribulin.¡±

 

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

 

Eisai presentations at the 2022 SABCS are as follows: